Back to Anacor Homepage Developing Drug Candidates Through Boron Chemistry
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Overview | Management | Board of Directors | Strategic Alliances | Partnering | Contact Us
    About - Management

We are a biopharmaceutical company developing small molecule therapeutics derived from our boron chemistry platform AN2690

 

David P. Perry
Chief Executive Officer

Kirk R. Maples, Ph.D.
Senior Vice President, Program Management

Jacob J. Plattner, Ph.D.
Senior Vice President, Research

Irwin A. Heyman, Ph.D.
Senior Vice President, Product Development

Kurt R. Jarnagin, Ph.D.
Vice President, Biological Research

James R. Marconi
Vice President, Finance and Controller

Lee T. Zane, M.D.
Vice President, Clinical Development